Title:
COMPOSITION FOR INHIBITING MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS)
Document Type and Number:
WIPO Patent Application WO/2015/182798
Kind Code:
A1
Abstract:
Disclosed is a novel use of a peptide including SEQ ID NO: 1, a peptide having at least 80% sequence identity to the peptide sequence, or a peptide as a fragment thereof. Specifically, disclosed is a use of the peptide for inhibiting myeloid-derived suppressor cells (MDSCs). The suppression problem of the immune response by MDSC can be solved by inhibiting MDSC. The peptide is used in combination with other anticancer agents and adjuvants, thereby effectively inhibiting MDSC, and thus can relieve, treat, or prevent MDSC-related diseases or symptoms. Furthermore, provided can be a vaccine having no side effects associated with MDSC, especially, a cancer vaccine, an anticancer kit, or an anticancer method.
Inventors:
KIM SANG JAE (KR)
MIDDLETON GARY (GB)
MIDDLETON GARY (GB)
Application Number:
PCT/KR2014/004760
Publication Date:
December 03, 2015
Filing Date:
May 28, 2014
Export Citation:
Assignee:
KAEL GEMVAX CO LTD (KR)
KIM SANG JAE (KR)
KIM SANG JAE (KR)
International Classes:
A61K38/10; A61K38/17; A61P35/00
Domestic Patent References:
| WO2011116299A2 | 2011-09-22 | |||
| WO2013135266A1 | 2013-09-19 |
Other References:
"Findings from Royal Marsden hospital has provided new data on pancreatic cancer", WEBSITE: PHARMACY CHOICE - PHARMACY NEWS ARTICLE, 31 March 2014 (2014-03-31), Retrieved from the Internet
ANNELS ET AL.: "The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 63, no. 2, pages 175 - 183, XP055240759, ISSN: 0340-7004
RASMUSSEN ET AL.: "Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 355, no. 1-2, 2010, pages 52 - 60, XP055240763, ISSN: 0022-1759
MAZZOLA ET AL.: "Aging, cancer, and cancer vaccines", IMMUNITY & AGEING, vol. 9, 2012, pages 1 - 11, XP055240764
ANNELS ET AL.: "The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 63, no. 2, pages 175 - 183, XP055240759, ISSN: 0340-7004
RASMUSSEN ET AL.: "Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 355, no. 1-2, 2010, pages 52 - 60, XP055240763, ISSN: 0022-1759
MAZZOLA ET AL.: "Aging, cancer, and cancer vaccines", IMMUNITY & AGEING, vol. 9, 2012, pages 1 - 11, XP055240764
Attorney, Agent or Firm:
KIM, SUN-YOUNG (KR)
κΉμμ (KR)
κΉμμ (KR)
Download PDF:
Previous Patent: OPTICAL MODULE
Next Patent: COMPOSITION FOR IMPROVING SKIN DISEASES COMPRISING HOVENIA DULCIS AND SEMEN ALLII TUBEROSI
Next Patent: COMPOSITION FOR IMPROVING SKIN DISEASES COMPRISING HOVENIA DULCIS AND SEMEN ALLII TUBEROSI